Inherited Genetics Steer Cancer Evolution: The Same Carcinogen, Yet Tumors Take Different Paths

Cancer is often described as the result of acquired mutations accumulating step by step, but mutations do not occur in a vacuum. A mouse study published in *Nature* shows that an individual's inherited genetic background may determine which damaged cells are more likely to become tumors, which driver mutations prevail, and how cancer cells subsequently reorganize their entire genomes.

The research team exposed four genetically distinct types of male mice to the same carcinogen, diethylnitrosamine (DEN), while controlling for sex, housing environment, and exposure conditions. The researchers then performed whole-genome sequencing, RNA sequencing, and histopathological analysis on 581 induced liver tumors, allowing them to compare acquired cancer-causing events across different inherited genetic backgrounds.

The results showed that genetic background affected not only susceptibility to cancer but also when tumors appeared. Tumor latency differed by dozens of weeks among the strains: C3H mice developed tumors at approximately 25 weeks, while CAROLI mice required approximately 78 weeks. The German Cancer Research Center's description of the study also noted that one strain required fewer genetic changes to complete malignant transformation and sustain tumor growth.

Tumors in all four strains almost invariably converged on activation of the MAPK signaling pathway, indicating that cancer cells exposed to the same carcinogenic pressure still shared a common endpoint. However, the genes driving this pathway, the specific amino acid changes, the mutation burden, and the patterns of clonal expansion varied with genetic background. The study also found that inherited background altered how acquired driver mutations affected cancer-related signaling networks such as p53.

The differences extended even to the stability of the entire genome. Whole-genome doubling occurred only in Braf mutation-driven CAROLI tumors, revealing a highly specific interaction: the same acquired driver event was accompanied by this large-scale genomic restructuring only when it occurred within a particular genetic background. This also shows that the name of a single mutation alone may not be sufficient to predict the subsequent evolutionary trajectory of a tumor.

This study remains a controlled mouse model of liver cancer and cannot directly demonstrate that human populations develop cancer in the same way. Human genetic variation, lifestyle exposures, and tumor types are more complex, and the relevant interactions will need to be validated in human cancer data. If the findings hold, cancer risk assessment, screening design, and precision treatment may need to consider both germline genetic background and acquired tumor mutations, rather than interpreting them separately.